Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Ameluz / Aminolevulinic acid hydrochloride for Superficial Basal Cell Carcinoma Treated with Red-Light Photodynamic Therapy

As of October 2026, MARA’s assessment finds Ameluz / Aminolevulinic acid hydrochloride’s reimbursement risk concentrated in safety and adverse effects, with evidence quality and robustness a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs patient population and subgroups: how closely the trial population matches the patients who would receive the drug in practice; payers often restrict funding to the groups where the evidence is strongest. The strength recorded in evidence quality and robustness carries weight because that domain asks how solid the underlying evidence is on its own terms — trial design, size and endpoints — before any question of price is reached.

Oncology

This rating sits within MARA’s Oncology coverage, alongside 165 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Ameluz demonstrated a significant improvement in clinical-plus-histological clearance over vehicle-PDT in the US phase III trial, with a composite clearance rate of 65.5% vs. 4.8%. In the European trial, it showed noninferiority to MAL-PDT with a clearance rate of 93.4% vs. 91.8%. However, there is no direct comparison with surgical excision or other active treatments like imiquimod or 5-FU.

Does the economic case hold at the expected price? — Cost effectiveness

No economic model, ICER, or cost-utility analysis was presented for Ameluz in sBCC.

Is there quality-of-life evidence payers weigh? — Quality of life

No validated HRQoL data were reported. Cosmetic outcomes and satisfaction were assessed but not through validated HRQoL instruments.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Ameluz treatment resulted in predictable phototoxicity, with 95.2% experiencing application-site pain. Severe AEs were rare and not treatment-related, but the high frequency of local reactions should be considered in treatment pathways.

Was the drug compared against what payers expect? — Comparator Selection

Vehicle-PDT was used in the US trial to establish drug contribution, while MAL-PDT was a relevant comparator in the European trial. However, no direct comparison with surgical excision or other first-line treatments was conducted.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trials primarily included older White patients with low-risk truncal or extremity lesions. There was limited representation of diverse populations, high-risk sites, or aggressive histologies.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Ameluz fits as a nonsurgical alternative for selected superficial lesions, especially where tissue preservation and cosmetic outcomes are important. It requires biopsy confirmation and structured follow-up.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource-use information was presented. The treatment requires multiple sessions and specialized equipment, but direct costs were not quantified.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The US trial was randomized and double-blind with histological confirmation, supporting internal validity. The European trial provided active comparison but had limitations in blinding and endpoint rigor.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

Uncertainty exists due to the lack of active comparison in the US trial, attrition in long-term follow-up, and absence of formal sensitivity analysis. The most decision-sensitive variables include five-year recurrence and treatment costs.

Be alerted when this rating changes:

Sample two-page MARA Rating report for the fictional drug Samplinib: page one with the rating, its key numbers and the past decisions on drugs in the same rating band; page two with the ten graded payer-side domains and the reasoning behind each
Every MARA rating is delivered as a two-page reasoned report (sample, fictional product) — see it in full
Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.